Home > Insider Trading > Filing (0000939767-21-000050)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
939767	Exelixis Inc.	EXEL	Biological Products, (No Disgnostic Substances) (2836)	043257395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1213140	Gisela Schwab	C/O Exelixis, Inc. 1851 Harbor Bay Parkway Alameda CA 94502	Pres, Prod Dev & Med Aff & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-13	100,000	$1.90	714,078	No	4	M	Direct
Common Stock	Disposition	2021-05-13	100,000	$25.38	614,078	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2021-05-13	100,000	$0.00	100,000	$1.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
150,000	2015-07-20	2022-02-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	14,880	Indirect	By 401(k)

Footnotes

Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 596 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.15 to $25.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 13, 2021.
The option, representing the right to purchase a total of 250,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.